atopic dermatitis – Prof. Marcus Maurer

EAACI biological guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis

422.

Agache, I.⁺, Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger T., Eyerich, K. Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Warner, A., Werfel, T., Palomares, O., and Jutel, M.: EAACI biological guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy 2021: 76; 988-1009. IF: 14.71

o.422

Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies

164.

Kühn, H., Kolkhir, P., Babina, M., Düll, M., Frischbutter, S., Fok, J. S., Jiao, Q., Metz, M., Scheffel, J., Wolf, K., Kremer, A. E., and Maurer, M.⁺: Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies. J. Allergy Clin. Immunol. 2021: 147; 456-469. IF: 14.29

r.164

Efficacy and safety of Dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines

411.

Agache, I.⁺, Song, Y., Posso, M., Alonso-Coello, P., Rocha, C., Solà, I., Beltran, J., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C.*, Palomares, O.*, and Jutel, M.*: Efficacy and safety of Dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy 2021: 76; 45-58. IF: 14.71

o.411

Innate immunity in atopic dermatitis

17.

Mrabet-Dahbi, S. and Maurer, M.: Innate immunity in atopic dermatitis. In: Shiohara T., Amagai, M., Homey, B., Nakanishi, K., Woodfolk, J. A., Bieber, T., Flohr, C., Schittek, B., Hayakawa, J., Yu, H.-S., Oranje, A. P., Schmid-Grendelmeier, P., and Akdis, C. A., editors: Current Problems in Dermatology „Atopic Dermatitis“. Basel: S. Karger Publishers, 2011

Anti-pruritic effect of sertaconazole 2% cream in atopic dermatitis subjects: a prospective, randomized, double-blind, vehicle-controlled, multi-centre clinical trial of efficacy, safety and local tolerability

248

Ständer, S.+, Metz, M., Ramos, M. H., Maurer, M. Schoepke, N., Tsianakas, A., Zeidler, C., and Luger, T. A.: Anti-pruritic effect of sertaconazole 2% cream in atopic dermatitis subjects: a prospective, randomized, double-blind, vehicle-controlled, multi-centre clinical trial of efficacy, safety and local tolerability. Acta Derm. Venereol. 2016: 96; 792-796. IF: 3.65

Interleukin-31 does not induce immediate itch in atopicdermatitis patients and healthy controls after skinchallenge

201	Hawro, T., Saluja, R., Weller, K., Altrichter, S., Metz, M., and Maurer, M.+: Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy 2014: 69; 113-117. IF: 6.03

o.201

Histamine and Antihistamines in Atopic Dermatitis

55.	Buddenkotte, J., Maurer, M., and Steinhoff, M.: Histamine and antihistamines in atopic dermatitis. Adv. Exp. Med. Biol. 2011: 709; 73-80. IF: 1.37

The role of IL-33 and mast cells in allergy and inflammation

98.	Saluja, R., Khan, M., Church, M. K., and Maurer, M.: The role of IL-33 and mast cells in allergy and inflammation. Clin. Transl. Allergy 2015: 5; 33. IF N/A

r.098

H1-Antihistamines and itch in atopic dermatitis

100.	Church, M. K. and Maurer, M.: H1-Antihistamines and itch in atopic dermatitis. Exp. Dermatol. 2015: 24; 332-333. IF: 2.67

r.100

Polidocanol inhibits cowhage – but not histamine-induced itch in humans

195	Hawro, T., Fluhr, J. W., Mengeaud, V., Redoulès, D., Church, M. K., Maurer, M. and Metz, M.+: Polidocanol inhibits cowhage – but not histamine-induced itch in humans. Exp. Dermatol. 2014: 23; 922-941. IF: 3.76